BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

BioAge Labs, Inc.NASDAQ: BIOA

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$22.15M, compared with -$12.64M a year earlier. Trailing-twelve-month EBITDA was -$89.21M.

Context

  • EBITDA amounted to 886.0% of revenue in FY2025.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -$89.59M (-12.4%) for the fiscal year ending Dec 2026, a step up from the -16.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.15M+14.1% QoQ
Last fiscal yearDec 2025
-$79.7M-16.2% YoY
LTMMar 2026
-$89.21M-28.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-75.3%-30.5%+44.8 pp
1 year-16.2%-12.4%+3.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(79.7M) USD
Year-over-year change
-16.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.4% is the 5th highest of 9, against a peer median of +1.3%.
  • EBITDA amounts to 864.8% of revenue for BIOA, versus a peer median of 44.8%.
BIOA Competitors
EBITDA for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$10.48M CAD-79.6%—3.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$1.03M USD——0.8%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$9.96M USD+38.2%—23.8%
HUMAHumacyte, Inc.LTM Mar 2026-$79.77M USD-33.1%—3956.7%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.21M USD-28.4%—864.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M USD+56.8%—258.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M USD+32.7%——
CABACabaletta Bio, Inc.LTM Mar 2026-$171.58M USD-48.1%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$179.89M USD-30.1%——
CGCCanopy Growth CorporationLTM Mar 2026-CA$205.34M CAD+57.2%—65.7%
Peer median (excluding BIOA) —+1.3%—44.8%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.